Valbiotis announces the positive results of a clinical bioavailability and mode of action study conducted on TOTUM 854 in the treatment of hypertension.

The results demonstrated a protective effect of TOTUM 854 on vascular wall cells and a reduction in angiotensin I-converting enzyme (ACE1) activity in humans.

These solid data confirm TOTUM 854's potential for reducing blood pressure in its early stages, which affect 123 million people in the United States and Europe. They are very promising for the final stage of TOTUM 854's clinical development", the company emphasizes.


Copyright (c) 2023 CercleFinance.com. All rights reserved.